#hepatitis C treatment

The burden of viral and nonviral liver disease remains high even in the setting of hepatitis C microelimination.

People with advanced fibrosis—not just cirrhosis—were at greater risk for hepatocellular carcinoma.

Greater political will and financial support for national programs are needed to eliminate viral hepatitis.

The three-drug combination cured most people who had experienced previous treatment failure.

People with hepatocellular carcinoma had improved survival after the advent of direct-acting antiviral therapy.

However, people with liver cirrhosis remain at risk and should continue screening even after being cured.

Left untreated, hepatitis C can lead to cirrhosis, liver cancer and the need for a liver transplant.

Liver cancer is now less likely to be caused by hepatitis B or C, but more likely to be caused by fatty liver disease or alcohol.

People who developed hepatocellular carcinoma after being cured of HCV had cirrhosis and worse liver function.

Universal HCV testing led to an increase in the number of pregnant women and infants diagnosed in a timely manner.

Men and Black people were more likely to have antibodies against hepatitis C virus.

Hepatocellular carcinoma can still occur after hepatitis C is cured, and risk factors differ for people with and without cirrhosis.

The number of people treated for hepatitis C hit a low point during the COVID-19 pandemic.

People treated with direct-acting antivirals had better overall survival than those whose hepatitis C remained untreated.

Despite limited testing and clinical visits, 95% of the study population was able to achieve a sustained virological response.

Hepatitis A and E usually resolve on their own, but hepatitis B and C can cause serious liver disease, including cirrhosis and liver cancer.